

Krebs Biochemicals & Industries Limited

CIN : L24110AP1991PLC103912



1st February, 2020

To,
The Manager,
Department of Corporate Relations,
BSE Limited,
P J Towers, Dalal Street,
Fort, Mumbai- 400001.

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.,
Exchange Plaza, BandraKurla Complex,
Bandra (E), Mumbai- 400051.

Dear Sir/Madam,


Sub: Submission of Quick Result.

We refer to the above mentioned subject, we herewith submit to the Exchange the quick result for the quarter ended 31st December, 2019 as approved by the Board of Directors at their meeting held on 1st February, 2020.

This is for the information and records of the Exchange, Please.

Thanking You,

Yours Faithfully,
For Krebs Biochemicals & Industries Limited


Taruni Banda
Company Secretary

Encl as above

CIN:L24110AP1991PLC103912

Corporate Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No: 8, Banjara Hills, Hyderabad - 500 034

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED AND NINE MONTHS ENDED DECEMBER 31, 2019

(Rs. In lacs)

1	The above results have been reviewed by the Audit Committee at its meeting held on 01st February 2020 and approved by the Board of Directors of the Company at its meeting held on 01st February 2020 The results are subjected to limited review by statutory auditors.
2	The Company is operating in one segment only hence no segment results have been disclosed.
3	The Company has adopted Ind AS-116, effective annual reporting period beginning April 1, 2019 and applied the standard to its leases. However, there is no impact on the financials of the Company.
4	The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015.
5	The figures for the corresponding previous period have been regrouped / reclassified wherever necessary, to make them comparable.

Date: 01.02.2020


Avinash Ravi
Managing Director
DIN : 01616152



Limited Review Report

**Review Report to
The Board of Directors,
KREBS BIOCHEMICALS & INDUSTRIES LIMITED**

- a) We have reviewed the accompanying statement of unaudited standalone financial results of **M/s. KREBS BIOCHEMICALS & INDUSTRIES LIMITED** ("the company") for the quarter ended **31st December, 2019** and the year to date from 1st April 2019 to 31st December 2019 (the "Statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with SEBI circular No CIR/CFD/FAC/62/2016 dated 5th July 2016.
- b) The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and SEBI circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express a conclusion on the statement based on our review.
- c) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- d) Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with relevant rules issued thereafter and other recognized accounting practices and policies has disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Bhavani & Co.
Chartered Accountants
Firm Registration No: 0121395

CA S Kavitha Padmini
Partner

Membership no: 229966

UDIN : 20229966 AAAA+7915

Place : Hyderabad
Date : 01/02/2020

